Acibadem Altunizade’s Published Pediatric BMT Program
Acibadem’s official Altunizade hospital page identifies an Adult and Pediatric Bone Marrow Transplantation Center. Its pediatric service page describes autologous, allogeneic and haploidentical pathways within the group’s program.
Acibadem Altunizade is the published partner program for this campaign, not the family’s only option. MedTransplant can also help families explore other verified programs or request a comparison.
Specialist Evaluation Comes Before a Transplant Plan
A diagnosis such as leukemia, thalassemia or sickle-cell disease does not by itself mean a child needs transplant. The pediatric hematology team must assess the exact condition, severity, treatment response, alternatives, risks and likely benefit.
An initial records review is not a diagnosis, treatment recommendation or confirmation that transplantation is appropriate.
Conditions Require Different Decisions
Some leukemias, bone-marrow failure disorders, immune conditions, inherited blood disorders and metabolic diseases may lead a specialist team to consider HSCT in selected circumstances. Many children receive other treatments instead or first.
Transplant Type Is Case-Specific
Autologous transplantation uses the child’s collected cells. Allogeneic transplantation uses donor cells; haploidentical transplantation is one possible allogeneic approach. The responsible team selects a pathway only after detailed review.
Donor Suitability and Child Safeguarding
A sibling, parent or other possible donor is not automatically suitable. HLA matching, donor health, consent, child safeguarding, cell source and any registry or legal requirements need separate specialist review.
MedTransplant does not find or promise donors. A potential donor requires an independent, hospital-led pathway with age-appropriate consent or authorization.
Records for Preliminary Pediatric Review
A structured file can help the hospital understand the referral question before a family travels.
- Pediatric hematology summary and confirmed diagnosis
- Pathology, bone-marrow, flow-cytometry, molecular and genetic reports
- Treatment timeline, response and complications
- Recent blood counts, organ-function and infection results
- Available HLA or family-donor information when clinically relevant
- Parent or legal-guardian identity and authorization
A Parent or Legal Guardian Can Start Case Review
The MedTransplant Case Review supports submission by a parent or legal guardian. The submitter should identify their relationship and confirm authorization while keeping the child’s information accurate and limited to what is relevant.
How MedTransplant Coordinates the Review
MedTransplant organizes available records, coordinates preliminary submission and communicates missing information or the hospital response. The pediatric team retains every diagnostic, treatment, donor and acceptance decision.
Families May Compare Verified Programs
Families may explore other verified hospital programs or ask MedTransplant for a practical comparison. A responsible comparison considers pediatric expertise, review requirements, clinical fit and continuity—not unsupported superiority claims.
Plan Family Travel After Hospital Feedback
Wait for a meaningful preliminary response before non-refundable bookings. Clarify who must travel, requested testing, expected assessment stages, accommodation needs and how a parent or guardian can remain with the child.
No Unsupported Prices, Outcomes or Guarantees
No fixed price, success rate or guarantee is published. Any proposed scope or quotation depends on the child’s evaluation, donor or cell-source work-up, treatment plan and hospital response.
Pediatric Follow-up Must Be Continuous
Before treatment, identify the local pediatric hematology team responsible after return. Infection monitoring, medicines, blood counts, immune recovery, vaccinations, growth and psychosocial support may require long-term coordination.
Family preparation by country
International pediatric pathways
Review parent- and guardian-focused preparation before travel from four campaign countries.
Frequently Asked Questions
Can a parent submit a child’s case from Acibadem Altunizade?
Yes. A parent or legal guardian can identify their relationship and authorization in the MedTransplant Case Review.
Does leukemia always require bone marrow transplant?
No. Treatment depends on the leukemia type, risk features, response and available alternatives. Pediatric specialists decide whether HSCT should be considered.
Does thalassemia or sickle-cell disease always require transplant?
No. Severity, current treatment, complications, donor options, alternatives and individual risks all matter.
Is a sibling automatically a suitable donor?
No. HLA matching, health, consent, safeguarding and the proposed cell source require separate hospital-led assessment.
Can MedTransplant find a donor?
No. MedTransplant does not find, recruit, sell, broker or guarantee donors.
Does submission guarantee the child’s acceptance?
No. Submission guarantees neither diagnosis, hospital acceptance, donor approval, transplantation, timing nor outcome.
Can families compare another pediatric program?
Yes. Acibadem Altunizade is the published partner for this campaign, while families may explore other verified programs or request comparison.
When should the family book travel?
Usually after the hospital reviews the available file and describes the possible next assessment steps.
Sources and verification
Pediatric medical responsibility
MedTransplant coordinates parent- or guardian-led case preparation and referral. Pediatric specialists make all diagnostic, treatment, donor and acceptance decisions.